3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
12
Parkinson Disease 4, Autosomal Dominant Lewy Body
8
Melanoma
6
Carcinoma, Renal Cell
6
Neoplasms
5
Neoplasm Metastasis
3
Esophageal Squamous Cell Carcinoma
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Liver Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Transitional Cell
2
Advanced Solid Tumor
2
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Sarcoma
1
Rhabdomyosarcoma
1
Recurrence
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Metastatic Castration-Resistant Prostate Cancer
1
Interventions
pembrolizumab
1
olaparib
1
lenvatinib
1
enzalutamide
1
belzutifan
1
Prednisone
1
Etoposide
1
Docetaxel
1
Dexamethasone
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Metastatic Castration-Resistant Prostate Cancer
×
lenvatinib
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled